ABOUT US
NEWS
Preclinical Findings on Rejuven’s RJV00...
Rejuven, an innovative biotechnical company committed to dermatology study, is developing recombinan...
17
2022-06
On June 13, 2022, the US FDA approved the phase I clinical trial of the RJV001 (NCT04821648). A tota...
17
2022-06
on February 28, 2022, Rejuven participated in the Enterprise Exhibition Day of Johnson & Johnson Inn...
15
2022-06
Rejuven continues to research biological drugs supported by Torch Program and has developed its core...
20
2021-12
On November 5, 2021, the fourth China International Import Expo (CIIE) was held in Shanghai. A total...
20
2021-12
On May 8, 2021, the final competition of "Startup @ Investment" Healthcare Innovation and Entreprene...